EA201101286A1 - Композиции биодоступных капсул некристаллического соединения альфа-(n-сульфонамидо)ацетамина - Google Patents

Композиции биодоступных капсул некристаллического соединения альфа-(n-сульфонамидо)ацетамина

Info

Publication number
EA201101286A1
EA201101286A1 EA201101286A EA201101286A EA201101286A1 EA 201101286 A1 EA201101286 A1 EA 201101286A1 EA 201101286 A EA201101286 A EA 201101286A EA 201101286 A EA201101286 A EA 201101286A EA 201101286 A1 EA201101286 A1 EA 201101286A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystallic
acetamine
sulphonamido
capsules
bio
Prior art date
Application number
EA201101286A
Other languages
English (en)
Inventor
Сачин Чандран
Раджеш Бабулал Ганди
Жак Калани Левон
Роберт Кевин Перрон
Кристофер П. Прайс
Кришнасуоми Сринивас Рагхаван
Исмат Улла
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201101286A1 publication Critical patent/EA201101286A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Представлены фармацевтические композиции в виде капсул, содержащие активное соединение (2R)-2-[[(4-хлорфенил)сульфонил][[2-фтор-4-(1,2,4-оксадиазол-3-ил)фенил]метил]амино]-5,5,5-трифторпентанамид, полиэтиленгликоль (PEG), полиэтиленгликоль витамин Е сукцинат, поливинилпирролидон (PVP) или соповидон (PVP-поливинилацетат), с лимонной кислотой или без нее.
EA201101286A 2009-04-14 2010-04-13 Композиции биодоступных капсул некристаллического соединения альфа-(n-сульфонамидо)ацетамина EA201101286A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16906109P 2009-04-14 2009-04-14
PCT/US2010/030862 WO2010120755A1 (en) 2009-04-14 2010-04-13 Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound

Publications (1)

Publication Number Publication Date
EA201101286A1 true EA201101286A1 (ru) 2012-04-30

Family

ID=42235859

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201101286A EA201101286A1 (ru) 2009-04-14 2010-04-13 Композиции биодоступных капсул некристаллического соединения альфа-(n-сульфонамидо)ацетамина

Country Status (14)

Country Link
US (1) US8252821B2 (ru)
EP (1) EP2419090B1 (ru)
JP (1) JP2012524092A (ru)
KR (1) KR20120022766A (ru)
CN (1) CN102395361A (ru)
AR (1) AR076305A1 (ru)
AU (1) AU2010236602A1 (ru)
BR (1) BRPI1015483A2 (ru)
CA (1) CA2758847A1 (ru)
EA (1) EA201101286A1 (ru)
MX (1) MX2011010514A (ru)
NZ (1) NZ595335A (ru)
TW (1) TW201041609A (ru)
WO (1) WO2010120755A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60232276D1 (de) 2001-12-20 2009-06-18 Bristol Myers Squibb Co Alpha-(n-sulfonamid)acetamidderivate als beta-amyloidinhibitoren
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
WO2011040797A2 (ko) 2009-10-02 2011-04-07 엘지전자 주식회사 하향링크 참조신호의 전송방법 및 장치
ES2565353T3 (es) 2010-12-16 2016-04-04 Borje S. Andersson Formulaciones farmacéuticas de azol para administración parenteral y métodos para la preparación y el uso de las mismas como tratamiento de enfermedades sensibles a los compuestos de azol
PL2701684T3 (pl) 2011-04-28 2018-09-28 Platform Brightworks Two, Ltd. Ulepszone preparaty pozajelitowe lipofilowych środków farmaceutycznych oraz sposoby ich wytwarzania i stosowania
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
CN113473971B (zh) * 2019-02-22 2024-07-02 詹森药业有限公司 药物配制品
CN115884773A (zh) * 2020-08-21 2023-03-31 詹森药业有限公司 药物制剂

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
NZ321293A (en) 1995-11-17 2001-04-27 Warner Lambert Co Sulfonamide inhibitors of matrix metalloproteinases
NZ333825A (en) 1996-07-22 2000-10-27 Monsanto Co Metalloprotease inhibitors particularly MMP-13
WO1998008490A1 (en) * 1996-09-01 1998-03-05 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
CZ20012545A3 (cs) 1999-01-27 2002-04-17 American Cyanamid Company Acetylenické sulfonamidthiolové inhibitory TACE
JP2002537376A (ja) 1999-02-26 2002-11-05 マーク・アンド・カンパニー・インコーポレイテッド 新規スルホンアミドおよびそれらの使用
JP2005506990A (ja) * 2001-10-19 2005-03-10 アイソテクニカ インコーポレーテッド 新規のシクロスポリン類似体のマイクロエマルションプレコンセントレート
DE60232276D1 (de) 2001-12-20 2009-06-18 Bristol Myers Squibb Co Alpha-(n-sulfonamid)acetamidderivate als beta-amyloidinhibitoren
CL2004000647A1 (es) 2003-03-31 2005-02-04 Wyeth Corp Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am
NZ547528A (en) 2003-10-29 2008-11-28 Elan Pharm Inc N-substituted benzene sulfonamides
US7163942B2 (en) 2004-04-01 2007-01-16 Pfizer Inc. Sulfonamide compounds for the treatment of neurodegenerative disorders
WO2005105050A1 (en) * 2004-04-28 2005-11-10 Procarrier, Inc. Oral formulation for delivery of poorly absorbed drugs
BRPI0513379A (pt) 2004-07-13 2008-05-06 Hoffmann La Roche derivados de sulfonamida
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
WO2006065710A1 (en) * 2004-12-14 2006-06-22 Wyeth Use of a 5-ht6 agonist for the treatment and prevention of neurodegenerative disorders
PE20080109A1 (es) 2006-02-17 2008-04-01 Wyeth Corp N-sulfonilacion selectiva de alcoholes sustituidos con 2-aminotrifluoralquilo
US7687666B2 (en) 2006-02-17 2010-03-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
BRPI0708493A2 (pt) * 2006-03-01 2011-05-31 Roskamp Res Llc compostos para inibição da produção de beta-amilóide
WO2008112249A1 (en) 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
CN102088855A (zh) 2008-05-08 2011-06-08 百时美施贵宝公司 2-芳基甘氨酰胺衍生物
KR20110133046A (ko) 2009-03-19 2011-12-09 브리스톨-마이어스 스큅 컴퍼니 베타 아밀로이드 펩티드 생성의 억제제로서의 신규 알파-(ｎ-술폰아미도)아세트아미드 화합물
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US20110071199A1 (en) 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
TW201043269A (en) 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Also Published As

Publication number Publication date
CN102395361A (zh) 2012-03-28
EP2419090B1 (en) 2013-02-13
EP2419090A1 (en) 2012-02-22
AR076305A1 (es) 2011-06-01
US20100260837A1 (en) 2010-10-14
AU2010236602A1 (en) 2011-10-13
NZ595335A (en) 2013-03-28
MX2011010514A (es) 2011-11-29
JP2012524092A (ja) 2012-10-11
CA2758847A1 (en) 2010-10-21
KR20120022766A (ko) 2012-03-12
WO2010120755A1 (en) 2010-10-21
BRPI1015483A2 (pt) 2016-04-26
US8252821B2 (en) 2012-08-28
TW201041609A (en) 2010-12-01

Similar Documents

Publication Publication Date Title
EA201101286A1 (ru) Композиции биодоступных капсул некристаллического соединения альфа-(n-сульфонамидо)ацетамина
EA200901319A1 (ru) Композиции для назального введения
EA200870219A1 (ru) Стабилизированные сукцинатом витамина е фармацевтические композиции, способы их получения и применения
MX2009007742A (es) Formulaciones farmaceuticas multi-fasicas de farmacos pobremente solubles en agua para una biodisponibilidad oral de variabilidad alimentada/en ayunas reducida y mejorada.
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
EA201390783A1 (ru) Биоразлагаемые композиции для доставки лекарственных средств
WO2011014850A3 (en) Topical eutectic-based formulations
MY174001A (en) Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
EA201490014A1 (ru) Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот
WO2009072007A3 (en) Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
NO20054555D0 (no) Farmasoytiske preparater som omfatter syrestabilisert insulin
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
EA200870545A1 (ru) Новые гетероциклические соединения
WO2006002077A3 (en) Stable pharmaceutical formulations of benzimidazole compounds
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
FR2949062B1 (fr) Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
WO2010127205A3 (en) Fixed dose drug combination formulations
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
BRPI0821373A2 (pt) Composições farmacêuticas contendo ao menos um princípio ativo protéico protegido de enzimas digestivas
WO2009060952A1 (ja) 新規製剤
WO2005107709A3 (en) Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin